abstract |
Disclosed is a pharmaceutical composition that binds to osteoprotegerin ligand (OPGL) and treats bone loss. A pharmaceutical composition for treating bone loss comprising an antibody comprising an H chain and an L chain, the H chain comprising a variable region comprising a specific amino acid sequence comprising CDR1, CDR2 and CDR3. The light chain comprises a variable region comprising other specific amino acid sequences, including CDR1, CDR2 and CDR3, and the antibody is induced by OPGL binding to a receptor activator (ODAR) of NF-kB. An antibody that inhibits osteoclast differentiation, wherein the bone loss is associated with osteoporosis, Paget's disease, osteomyelitis, hypercalcemia, osteopenia, osteonecrosis or rheumatoid arthritis cartilage loss and joint erosion A pharmaceutical composition for treating bone loss, wherein the antibody is a fully human type. Then antibodies that interact are described. [Selection figure] None |